Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
On Demand
Favorite
Facebook
Tweet
Print
Renuka Kapoor, PhD
Scientific Investigator
GSK
Disclosure(s): GSK: Employee, Stocks/Bonds (Public Company)
Poster(s):
(P-1174)
In vitro
Activity of Gepotidacin and Comparator Agents Against a Collection of
Escherichia coli
and
Klebsiella pneumoniae
Urine Isolates From the United States During 2023
Tuesday, October 21, 2025
12:15 PM - 1:30 PM
US ET
(P-1203) Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
Tuesday, October 21, 2025
12:15 PM - 1:30 PM
US ET
(P-1204) Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023)
Tuesday, October 21, 2025
12:15 PM - 1:30 PM
US ET
(P-1213) Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
Tuesday, October 21, 2025
12:15 PM - 1:30 PM
US ET
(P-1214) In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
Tuesday, October 21, 2025
12:15 PM - 1:30 PM
US ET
